

University of Groningen

Do we need new trials of procalcitonin-guided antibiotic therapy? A response

van Oers, Jos A. H.; Nijsten, Maarten W.; de lange, Dylan W.

Published in:
Critical Care

DOI:
[10.1186/s13054-018-2008-y](https://doi.org/10.1186/s13054-018-2008-y)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van Oers, J. A. H., Nijsten, M. W., & de lange, D. W. (2018). Do we need new trials of procalcitonin-guided antibiotic therapy? A response. *Critical Care*, 22(83). <https://doi.org/10.1186/s13054-018-2008-y>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

LETTER

Open Access



Do we need new trials of procalcitonin-guided antibiotic therapy? A response

Jos A. H. van Oers^{1*}, Maarten W. Nijsten² and Dylan W. de Lange³

See related Commentary by Lisboa et al., <https://ccforum.biomedcentral.com/articles/10.1186/s13054-018-1948-6>

Antibiotic treatment needs to be short, appropriate (focused on the right pathogen), and adequate (at the right dosage). And still, many physicians treat patients for too long. A recent meta-analysis on procalcitonin (PCT)-guided antibiotic treatment in acute respiratory infections [1] showed that antibiotics could be shortened from 8.1 to 5.7 days. The key question is, why do physicians treat for so long? The answer may be fear! Fear of undertreatment.

We read with great interest the commentary by Lisboa and colleagues in *Critical Care* [2] in which they question the clinical utility of this meta-analysis [1]. They concluded that populations in previous trials were not receiving best care, had less adherence to PCT algorithms, and lacked information on specific conditions and populations. As authors of the largest study included in this meta-analysis, the Stop Antibiotics on Procalcitonin guidance Study (SAPS) [3], we want to respond. SAPS was a pragmatic randomized controlled trial in the Netherlands with 1546 adult ICU patients with antibiotics for a presumed infection. We demonstrated a highly significant reduction in initial antibiotic duration (5.0 vs 7.0 days). The median duration of antibiotic treatment (DOT) in the control group of the total population was 7 days (interquartile range (IQR) 4–11 days). Of these patients, 65% had a presumed pulmonary infection. Dutch national guidelines recommend an antibiotic duration for moderate-severe community-acquired pneumonia (CAP) of 5 days [4]. No such advice exists for severe pneumonia admitted to the ICU. The median DOT in the control group in CAP was 7 days (IQR 4–10 days), 6 days (IQR 4–10 days) in hospital-acquired pneumonia and 7 days (IQR 5–11 days) in ventilator-associated pneumonia. The wide IQR suggests that physicians are reluctant to trust guidelines and prefer to prolong antibiotic treatment if they

believe it is necessary. Moreover, physicians may perform even better in clinical trials, because they know they are being watched, commonly referred to as the “Hawthorne effect”. In SAPS the patients were already on antibiotics. When a PCT-stopping criterion was reached antibiotics were stopped in 53% of the patients within 48 h. It was a stopping advice. Sensitivity and specificity are not high enough to withhold antibiotics on PCT alone. And indeed, PCT is no holy grail. Like other biomarkers, there are numerous non-infectious inflammatory processes, i.e., trauma, surgery, and acute kidney injury, in which PCT can be elevated. But such conditions were well balanced between both groups.

Acknowledgements

Not applicable.

Funding

No funding.

Availability of data and materials

Not applicable.

Authors' contributions

JO, MN, and DL made equal contributions. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

No financial or non-financial competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Intensive Care Medicine, Elisabeth Tweesteden Ziekenhuis, P.O. Box 90151, 5000 LC Tilburg, the Netherlands. ²Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ³Department of Intensive Care Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.

* Correspondence: jah.vanoers@etzn.nl

¹Department of Intensive Care Medicine, Elisabeth Tweesteden Ziekenhuis, P.O. Box 90151, 5000 LC Tilburg, the Netherlands

Full list of author information is available at the end of the article



Received: 15 February 2018 Accepted: 26 February 2018

Published online: 23 March 2018

References

1. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. *Lancet Infect Dis.* 2018;18:95–107.
2. Lisboa T, Salluh J, Povoia P. Do we need new trials of procalcitonin guided antibiotic therapy? *Crit Care.* 2018;22:17.
3. De Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized controlled, open-label trial. *Lancet Infect Dis.* 2016;16:819–27.
4. Wiersinga W, Bonten MJ, Boersma WG, et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). *Neth J Med.* 2018;76:4–13.